Research programme: oncology therapeutics - Globavir

Drug Profile

Research programme: oncology therapeutics - Globavir

Alternative Names: GBV 4086; GBV-1012; GBV-1028; GBV-1073; GBV-2034; GBV-3019

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Globavir Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; CCR4 receptor antagonists; CXCR4 receptor antagonists; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Sep 2016 Globavir plans a phase Ia/IIb trial for Cancer in USA (Globavir, pipeline, September 2016)
  • 09 Jul 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top